The cannabinoid WIN55,212-2 abrogates dermal fibrosis in scleroderma bleomycin model

Annals of the Rheumatic Diseases

Volumn 70, Issue 4, 2011, Pages 695-699

  Balistreri, Epifania ^a   Garcia Gonzalez, Estrella ^a   Selvi, Enrico ^a   Akhmetshina, Alfiya ^b   Palumbo, Katrin ^b   Lorenzini, Sauro ^a   Maggio, Roberta ^a   Lucattelli, Monica ^a   Galeazzi, Mauro ^a   Distler, Jörg W H ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; CONNECTIVE TISSUE GROWTH FACTOR; HYDROXYPROLINE; PLATELET DERIVED GROWTH FACTOR BB; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SKIN FIBROSIS; SKINFOLD THICKNESS;

ANIMALS; BENZOXAZINES; BLEOMYCIN; DERMATOLOGIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FIBROBLASTS; FIBROSIS; MICE; MICE, INBRED DBA; MORPHOLINES; NAPHTHALENES; PLATELET-DERIVED GROWTH FACTOR; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 79952363189     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.137539     Document Type: Article

References (19)

1. Varga J, Abraham D. Systemic sclerosis :a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67. (Pubitemid 46348510)
2. Abraham DJ, Eckes B, Rajkumar V, et al. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 2007;9:136-43. (Pubitemid 46932720)
3. Ihn H. The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. Arch Immunol Ther Exp (Warsz) 2002;50:325-31. (Pubitemid 35434568)
4. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-27.
5. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 2010;37:11-25.
6. Kretzschmar M, Massagué J. SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev 1998;8:103-11
7. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003;48:1964-78.
8. Teixeira-Clerc F, Julien B, Grenard P, et al. T he endocannabinoid system as a novel target for the treatment of liver fibrosis. Pathol Biol 2008;56:36-8.
9. Demuth D G, Molleman A. Cannabinoid signalling. Life Sci 2006;78:549-63.
10. Parfieniuk A, Flisiak R. Role of cannabinoids in chronic liver diseases. World J Gastroenterol 2008;14:6109-14.
11. Michalski CW, Maier M, Erkan M, et al. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS ONE 2008;3:e1701.
12. Akhmetshina A, Dees C, Busch N, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009;60:1129-36.
13. Servettaz A, Kavian N, Nicco C, et al. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol 2010;177:187-96.
14. Garcia-Gonzalez E, Selvi E, Balistreri E, et al. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology (Oxford) 2009;48:1050-6.
15. Kivirikko K I, Ganser V, Engel J, et al. Comparison of poly-L-proline I and II as inhibitors of protocollagen hydroxylase. Hoppe-Seyler's Z Physiol Chem 1967;348:1341-4.
16. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 2008;47 (Suppl 5):v2-4.
17. Yamamoto T. The bleomycin-induced scleroderma model:what have we learned for scleroderma pathogenesis? Arch Dermatol Res 2006;297:333-44.
18. Yamamoto T. Animal model of systemic sclerosis. J Dermatol 2010;37:26-41.
19. Lakos G, Takagawa S, Chen SJ, et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004;165:203-17. (Pubitemid 38821828)